We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

97 hedge funds and large institutions have $348M invested in iShares US Pharmaceuticals ETF in 2017 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 35 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

26% more capital invested

Capital invested by funds: $276M → $348M (+$71.3M)

24.64% more ownership

Funds ownership: 120.84% → 145.48% (+25%)

5% more funds holding

Funds holding: 92 → 97 (+5)

26% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 35

Holders
97
Holders Change
+5
Holders Change %
+5.43%
% of All Funds
2.41%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
17
Increased
26
Reduced
35
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CI
Clal Insurance
Israel
+$66.8M
2
MTWSIF
Mivtachim The Workers Social Insurance Fund
Israel
+$5.69M
3
MIAN
Mariner Independent Advisor Network
Kansas
+$5.41M
4
TSS
Two Sigma Securities
New York
+$5.39M
5
CS
Credit Suisse
Switzerland
+$4.03M

Top Sellers

1
BWL
Bogart Wealth LLC
Virginia
-$12.4M
2
Bank of America
Bank of America
North Carolina
-$8.87M
3
Morgan Stanley
Morgan Stanley
New York
-$6.58M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.68M
5
TC
Telemus Capital
Michigan
-$2.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
CTC
76
Central Trust Company
Missouri
$81K – – –
GWS
77
Glassman Wealth Services
Virginia
$70K – – –
FANJ
78
Financial Architects (New Jersey)
New Jersey
$57K +$149 +3 +0.3%
IWM
79
IHT Wealth Management
Illinois
$56K -$10.2K -207 -13%
VWM
80
Valley Wealth Managers
New Jersey
$45K – – –
FCMT
81
Founders Capital Management (Texas)
Texas
$43K +$42.2K +852 New
WTC
82
WhitTier Trust Company
Nevada
$38K – – –
CFD
83
Creative Financial Designs
Indiana
$26K -$86.1K -1,740 -77%
FFW
84
Fusion Family Wealth
New York
$26K – – –
Northwestern Mutual Wealth Management
85
Northwestern Mutual Wealth Management
Wisconsin
$23K -$19K -384 -45%
AA
86
AlphaMark Advisors
Kentucky
$17K – – –
NFG
87
Next Financial Group
Texas
$16K -$228K -4,602 -94%
CDIA
88
Capital Directions Investment Advisors
Georgia
$15K – – –
DSC
89
Duncker Streett & Co
Missouri
$15K – – –
Fifth Third Bancorp
90
Fifth Third Bancorp
Ohio
$14K – – –
GWM
91
Geneos Wealth Management
Colorado
$9K – – –
WIM
92
Westside Investment Management
California
$8.23K +$8.17K +165 New
BC
93
Bartlett & Co
Ohio
$5K – – –
DADC
94
D.A. Davidson & Co
Montana
$5K +$5.64K +114 New
AssetMark Inc
95
AssetMark Inc
California
$2K +$2.38K +48 New
AP
96
Advisors Preferred
Maryland
$20 +$19.5K +393 New
BWL
97
Bogart Wealth LLC
Virginia
– -$12.4M -263,424 Closed
TC
98
Telemus Capital
Michigan
– -$2.31M -48,990 Closed
Wolverine Trading
99
Wolverine Trading
Illinois
– -$436K -9,249 Closed
BFS
100
Bradley Foster & Sargent
Connecticut
– -$255K -5,400 Closed
1 2 3
4
5

IHE Hedge Fund Activity: Q1 2017 in Review

97 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2017, worth a combined $348M — up 26% from $276M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new IHE positions and 11 closed out — a net gain of 6 holders — while 26 added to existing stakes and 35 trimmed.

The largest buyer was Clal Insurance, adding an estimated $66.8M. The largest seller was Bogart Wealth LLC, exiting entirely with an estimated $12.4M sold.

  • 97 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2017, up from 92 in Q4 2016.
  • Funds reported $348M of iShares US Pharmaceuticals ETF stock for Q1 2017, up 26% quarter-over-quarter.
  • 17 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2017 and 11 closed out, a net change of +6 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q1 2017 was Clal Insurance, an estimated $66.8M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q1 2017 was Bogart Wealth LLC, an estimated $12.4M sold.

Based on aggregated 13F filings for Q1 2017.